FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis

Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer

(2014) Jae Myoung Suh et al.   NATURE

Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis

(2014) Rachel J Perry et al.   NATURE MEDICINE

Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways

(2013) Daniel F. Vatner et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

FGF19 action in the brain induces insulin-independent glucose lowering

(2013) Gregory J. Morton et al.   JOURNAL OF CLINICAL INVESTIGATION

Fibroblast Growth Factor-19 Action in the Brain Reduces Food Intake and Body Weight and Improves Glucose Tolerance in Male Rats

(2012) Karen K. Ryan et al.   ENDOCRINOLOGY

A PPARγ–FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis

(2012) Johan W. Jonker et al.   NATURE

Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2

(2011) F. R. Jornayvaz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis

(2011) S. Kir et al.   SCIENCE

Resistance to High-Fat Diet-Induced Obesity and Insulin Resistance in Mice with Very Long-Chain Acyl-CoA Dehydrogenase Deficiency

(2010) Dongyan Zhang et al.   Cell Metabolism

FGF-1: From Biology Through Engineering to Potential Medical Applications

(2008) Malgorzata Zakrzewska et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Mini-Review: Endocrine Actions of Fibroblast Growth Factor 19

(2008) Stacey Jones   MOLECULAR PHARMACEUTICS